Exclusive: Mytos inks cell therapy manufacturing deals with three European biotechs news2025-09-03T07:00:17+00:00September 3rd, 2025|Endpoints News|
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pactnews2025-09-02T15:34:54+00:00September 2nd, 2025|Endpoints News|
Arrowhead piques Novartis’ neuro interest with $200M upfront dealnews2025-09-02T14:59:15+00:00September 2nd, 2025|Endpoints News|
AbbVie’s Gilgamesh deal highlights pharma’s one-asset mindnews2025-08-29T10:53:43+00:00August 29th, 2025|Endpoints News|
Prothena reports Phase 1 Alzheimer’s data, noting high ARIA-E eventsnews2025-08-28T14:37:50+00:00August 28th, 2025|Endpoints News|
Novo’s first obesity deal under new CEO is a $550M pact with RNA startup Replicatenews2025-08-28T11:00:46+00:00August 28th, 2025|Endpoints News|
Regeneron’s rare disease drug succeeds in Phase 3 studynews2025-08-26T15:52:53+00:00August 26th, 2025|Endpoints News|
Novartis pays $30M to Leqembi creator for access to blood-brain barrier technews2025-08-26T15:05:22+00:00August 26th, 2025|Endpoints News|
BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltranews2025-08-25T16:02:36+00:00August 25th, 2025|Endpoints News|
AbbVie to buy psychedelic drug from partner Gilgameshnews2025-08-25T14:56:10+00:00August 25th, 2025|Endpoints News|
